Stay updated on GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%
- Check21 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
- Check29 days agoChange DetectedThe web page has removed a service alert regarding planned maintenance and updated the version information. Additionally, a date has been deleted.SummaryDifference5%
- Check36 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.8%
- Check43 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.3%
- Check50 days agoChange DetectedThe web page now includes a service alert regarding planned maintenance starting July 25th, indicating that most services will be unavailable for over 24 hours beginning at 9 PM EDT.SummaryDifference4%
Stay in the know with updates to GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.